Application of CRISPR/Cas9 in Treating Hepatitis B Virus
Journal of Liver Cancer
;
: 111-116, 2017.
Article
in English
| WPRIM
| ID: wpr-120522
ABSTRACT
The advent of oral antiviral agents has revolutionized hepatitis B treatment. It has led to decreased incidence and mortality related to hepatocellular carcinoma. However, although nucleos(t)ide analogs (NA) are fast and potent in inhibiting hepatitis B virus (HBV) polymerase and reverse transcriptase activity, complete cure of the virus is not possible. The complete eradication of HBV requires the covalently-closed-circular DNA (cccDNA) to be eliminated. Novel gene editing methods, such as zing finger nucleases, transcription activator-like effector nucleases, and the clustered regularly interspaced short palindromic repeats/Cas9 (CRISPR/Cas9) system, designed to target specific DNA sequences has great potential for therapeutic application. Among these, the CRISPR/Cas9 system may be the most feasible approach to eradicate HBV cccDNA. Further studies are needed to develop a more efficient and safer method of delivery using the CRISPR/Cas9 system to achieve complete cure of chronic hepatitis B.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Antiviral Agents
/
DNA
/
DNA, Circular
/
Base Sequence
/
Hepatitis B virus
/
Incidence
/
Mortality
/
RNA-Directed DNA Polymerase
/
Carcinoma, Hepatocellular
/
Hepatitis B, Chronic
Type of study:
Incidence study
/
Prognostic study
Language:
English
Journal:
Journal of Liver Cancer
Year:
2017
Type:
Article
Similar
MEDLINE
...
LILACS
LIS